David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's ...

For years, Roche has been increasing medicine production in the United States. That could pay off for the drug maker as ...

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways in which the ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

The Basel-based company said the investment would go toward high-tech research and development sites and new manufacturing ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

Seductive Reasoning,” a flop that preceded the Roches’ debut, has a fluctuating sonic palette, contributions from Paul Simon ...